The Food and Drug Administration yesterday issued a warning letter to CanaRx, a company that contracts with employers to provide select prescription drugs to employees, for facilitating the distribution of unapproved and misbranded drugs. “In this scheme, CanaRx facilitates foreign physicians rewriting the employee’s U.S. prescription, and then supplies the employee with unapproved versions of FDA-approved drugs purportedly sourced from Canada, the United Kingdom or Australia that are represented to have undergone review from those countries’ drug regulatory systems,” FDA said. “This is particularly troublesome, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s ‘insurance’ plan and may not question their legitimacy.” The letter lists more than 150 websites affiliated with the company. FDA said health care providers and consumers should report any adverse events related to drugs provided by CanaRx to its MedWatch program.

Related News Articles

Headline
The Senate Health, Education, Labor and Pensions Committee yesterday voted 12-11 along party lines to recommend the confirmation of Brian Christine, M.D., to…
Chairperson's File
Public
This month Congress enacted the One Big Beautiful Bill Act — a sweeping package that contained many of President Trump’s legislative priorities on taxes,…
Headline
The Centers for Medicare & Medicaid Services July 15 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
The AHA July 2 expressed support for the Resident Physician Shortage Reduction Act (H.R. 3890), bipartisan legislation that would add 14,000 Medicare-funded…
Headline
The House July 3 voted 218-214 to pass the final version of the One Big Beautiful Bill Act (H.R. 1), which enacts many of President Trump’s legislative…
Headline
The House has begun consideration of the Senate-passed version of the One Big Beautiful Bill Act (H.R. 1). This continues to be a fluid…